PIACENTINI, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.286
EU - Europa 14.995
AS - Asia 12.933
SA - Sud America 1.768
AF - Africa 355
OC - Oceania 75
Continente sconosciuto - Info sul continente non disponibili 23
Totale 54.435
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.783
IT - Italia 4.952
SG - Singapore 3.849
CN - Cina 3.154
GB - Regno Unito 2.540
IE - Irlanda 2.197
HK - Hong Kong 1.486
VN - Vietnam 1.394
BR - Brasile 1.288
DE - Germania 1.180
SE - Svezia 1.022
BD - Bangladesh 697
FR - Francia 563
FI - Finlandia 541
RU - Federazione Russa 484
UA - Ucraina 400
IN - India 398
KR - Corea 347
ID - Indonesia 293
TR - Turchia 288
CA - Canada 274
NL - Olanda 207
BG - Bulgaria 179
AR - Argentina 158
TW - Taiwan 144
JP - Giappone 143
MX - Messico 132
IQ - Iraq 120
ES - Italia 104
PL - Polonia 104
ZA - Sudafrica 81
LT - Lituania 79
PK - Pakistan 76
CO - Colombia 73
AU - Australia 72
CL - Cile 68
BE - Belgio 65
MY - Malesia 64
AE - Emirati Arabi Uniti 60
EC - Ecuador 60
EG - Egitto 59
AT - Austria 53
VE - Venezuela 52
CZ - Repubblica Ceca 45
SA - Arabia Saudita 43
IR - Iran 42
PH - Filippine 42
MA - Marocco 39
JO - Giordania 38
KE - Kenya 34
CH - Svizzera 30
TH - Thailandia 30
NP - Nepal 29
PY - Paraguay 29
RO - Romania 29
UZ - Uzbekistan 28
MD - Moldavia 25
AL - Albania 23
IL - Israele 22
TN - Tunisia 22
AZ - Azerbaigian 21
DZ - Algeria 20
GR - Grecia 20
DO - Repubblica Dominicana 19
HU - Ungheria 19
ET - Etiopia 17
EU - Europa 17
NG - Nigeria 17
PT - Portogallo 16
PE - Perù 15
DK - Danimarca 14
LB - Libano 14
SI - Slovenia 14
SY - Repubblica araba siriana 14
BO - Bolivia 13
JM - Giamaica 13
MK - Macedonia 13
CR - Costa Rica 12
RS - Serbia 12
HN - Honduras 11
LV - Lettonia 11
BH - Bahrain 10
KZ - Kazakistan 10
OM - Oman 10
UY - Uruguay 10
AO - Angola 9
BY - Bielorussia 9
CI - Costa d'Avorio 9
PA - Panama 9
CY - Cipro 8
MT - Malta 8
QA - Qatar 8
SK - Slovacchia (Repubblica Slovacca) 8
HR - Croazia 7
KG - Kirghizistan 7
PR - Porto Rico 7
SN - Senegal 7
KH - Cambogia 6
KW - Kuwait 6
LK - Sri Lanka 6
Totale 54.309
Salva come PNG Salva come JPEG
Città #
Singapore 2.587
Ashburn 2.576
Santa Clara 2.453
Dublin 2.189
Fairfield 1.752
Chandler 1.433
Hong Kong 1.432
Southend 1.325
San Jose 1.160
Woodbridge 1.013
Houston 793
Beijing 753
Council Bluffs 742
Dearborn 735
Seattle 724
Nyköping 668
Ann Arbor 666
Hefei 644
Wilmington 624
Jacksonville 608
Cambridge 535
London 522
Dallas 509
New York 496
Milan 467
Ho Chi Minh City 439
Los Angeles 418
Helsinki 402
The Dalles 365
Modena 337
Rome 327
Hanoi 312
Seoul 303
Chicago 237
Jakarta 229
Munich 209
Lauterbourg 197
Shanghai 196
Bologna 189
San Diego 183
Princeton 174
Sofia 169
Moscow 158
Eugene 141
Buffalo 134
Izmir 132
São Paulo 123
Frankfurt am Main 118
Dong Ket 112
Columbus 109
Orem 109
Fremont 106
Redwood City 104
Naples 98
Tokyo 89
Bremen 77
Salt Lake City 77
Phoenix 76
Florence 75
Boardman 74
Warsaw 74
Guangzhou 70
Falls Church 67
Brooklyn 66
Turin 65
Reggio Emilia 64
Toronto 63
Bari 59
Redondo Beach 57
Taichung 56
Chennai 55
Da Nang 55
Tampa 52
Genoa 51
Parma 51
Atlanta 50
Mumbai 50
Baghdad 49
Brussels 49
Haiphong 49
Montreal 48
Amsterdam 46
Palermo 46
Nuremberg 44
Turku 44
Norwalk 43
Elk Grove Village 40
Rio de Janeiro 40
Denver 39
Johannesburg 38
Ottawa 38
Des Moines 37
San Francisco 37
Mexico City 36
Nanjing 36
Paris 36
San Giuliano Milanese 35
Stockholm 35
Verona 34
Kent 33
Totale 35.941
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.158
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 619
Oxford Manuale di Medicina Clinica 554
Abemaciclib: eventi avversi e riduzione di dose. 524
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 491
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 452
RISULTATI DELLA RADIOTERAPIA PANENCEFALICA (WBRT) NELLE METASTASI CEREBRALI DA CARCINOMA DELLA MAMMELLA: STUDIO RETROSPETTIVO SUL RUOLO PROGNOSTICO DEI FATTORI BIOLOGICI 445
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 436
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 428
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 427
GD2 expression in breast cancer. 426
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer 423
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 420
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 417
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 411
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial 408
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 402
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 396
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 395
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 386
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 384
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 380
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 379
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 379
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 375
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 373
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 371
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 370
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 369
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 368
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 365
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 361
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 360
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 360
Molecular Profile, as detected with Mass-Array Spectrometry (Sequenom platform), in primary and metastatic breast carcinoma treated with Exemestane + Everolimus 356
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 354
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 353
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 351
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 350
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 350
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 345
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 342
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 337
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 336
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 334
Tumor Stroma Manipulation By MSC 331
Achievements and unmet needs in the management of advanced ovarian cancer 329
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 329
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 328
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 323
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. 323
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 320
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 316
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 316
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 316
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 314
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 314
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 312
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 311
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 311
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 309
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 309
Immune characterization of breast cancer metastases: prognostic implications. 307
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 307
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 306
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 305
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 304
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 303
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 298
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 298
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 297
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 296
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 293
Breast Location for De Novo Extramedullary Myeloid Sarcoma 288
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 288
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 288
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 287
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 286
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 286
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 281
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 280
Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study 279
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 279
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 275
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 273
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 272
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 271
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 271
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer 271
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 267
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 267
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 264
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 263
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 263
Prognostic Factors for Breast Cancer: an Immunomorphological Update 260
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). 260
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 260
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 260
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 258
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 257
Totale 34.699
Salva come PNG Salva come JPEG
Categoria #
all - tutte 186.672
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 186.672
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021309 0 0 0 0 0 0 0 0 0 0 0 309
2021/20223.347 133 383 286 129 124 264 152 199 366 301 594 416
2022/20236.486 494 585 344 417 410 514 111 388 2.573 114 325 211
2023/20243.725 179 203 239 292 496 314 342 569 150 204 298 439
2024/20259.842 357 209 270 727 1.882 1.501 628 693 967 583 772 1.253
2025/202619.140 1.211 601 1.616 1.833 2.728 1.255 2.462 1.043 1.812 1.947 1.506 1.126
Totale 54.828